Pier 88 Investment Partners LLC Raises Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pier 88 Investment Partners LLC lifted its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 296.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 390,960 shares of the company's stock after acquiring an additional 292,370 shares during the quarter. Pier 88 Investment Partners LLC owned 0.63% of Pyxis Oncology worth $383,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in PYXS. Bank of America Corp DE boosted its holdings in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after purchasing an additional 9,062 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after acquiring an additional 10,000 shares during the period. Barclays PLC boosted its position in shares of Pyxis Oncology by 20.2% during the fourth quarter. Barclays PLC now owns 77,013 shares of the company's stock worth $121,000 after purchasing an additional 12,924 shares in the last quarter. ProShare Advisors LLC bought a new stake in Pyxis Oncology in the 4th quarter valued at $26,000. Finally, Jane Street Group LLC increased its position in shares of Pyxis Oncology by 36.6% in the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock valued at $106,000 after acquiring an additional 18,128 shares during the last quarter. 39.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Pyxis Oncology in a research note on Monday, May 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Pyxis Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Price Performance

Shares of PYXS remained flat at $1.13 during trading hours on Tuesday. 139,621 shares of the stock traded hands, compared to its average volume of 717,491. Pyxis Oncology, Inc. has a 52 week low of $0.83 and a 52 week high of $5.39. The business's fifty day simple moving average is $1.20 and its 200-day simple moving average is $1.22. The company has a market capitalization of $70.00 million, a price-to-earnings ratio of -0.71 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). As a group, equities analysts anticipate that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.